Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Takeaways - MDSpire

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • By

  • Brunet, Louise

  • Busiah, Kanetee

  • Moser, Mireille

  • Papadakis, Georgios E.

  • May 21, 2026

  • 0 min

Share

  • 1

    GnRH agonists and estrogens in GAHT do not negatively impact metabolic health in adult transgender women.

  • 2

    Body mass index, fat mass index, and visceral adipose tissue remained unchanged during GAHT.

  • 3

    GAHT resulted in a significant reduction in lean mass indices after 12 months of treatment.

  • 4

    Participants showed an increase in plasma HDL-cholesterol levels during GAHT.

  • 5

    The percentage of participants with low bone mineral density decreased from 41% to 27% after 12 months of GAHT.

Original Source(s)

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • by Brunet, Louise , Busiah, Kanetee , Moser, Mireille , Papadakis, Georgios E.

  • May 21, 2026

Related Content

Associations of Overweight and Obesity Indicators with Cardiometabolic Risk Profile in Children and Adolescents with Congenital Heart Disease

Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care

Ethics of non-oncological fertility preservation from the perspective of the four principles of bioethics